Published in Nat Rev Gastroenterol Hepatol on January 08, 2013
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut (2014) 1.48
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis (2014) 1.35
A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int (2015) 1.01
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol (2015) 0.84
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2013) 0.84
Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. Lab Invest (2016) 0.83
Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol (2013) 0.81
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol (2013) 0.80
MicroRNAs in Cholangiopathies. Curr Pathobiol Rep (2014) 0.80
MicroRNAs and benign biliary tract diseases. Semin Liver Dis (2015) 0.78
Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology (2016) 0.76
A Lumpy Bumpy Liver. Gastroenterology Res (2015) 0.75
Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial. Trials (2015) 0.75
Creating an effective clinical registry for rare diseases. United European Gastroenterol J (2015) 0.75
Polycystic Liver Disease: The Benefits of Targeting cAMP. Clin Gastroenterol Hepatol (2016) 0.75
Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes. Eur J Hum Genet (2016) 0.75
Medical therapy for polycystic liver disease. Ann R Coll Surg Engl (2016) 0.75
Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data. Eur Radiol (2016) 0.75
Functional Budd-Chiari Syndrome Associated With Severe Polycystic Liver Disease. Clin Med Insights Gastroenterol (2017) 0.75
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Polycystic kidney disease. Annu Rev Med (2009) 4.78
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol (2008) 4.07
Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol (2011) 3.73
Somatostatin and its receptor family. Front Neuroendocrinol (1999) 3.69
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet (2011) 3.18
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol (2007) 2.44
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2007) 2.42
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Polycystic disease of the liver. Hepatology (2004) 1.94
Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet (2003) 1.77
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant (2012) 1.61
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther (2009) 1.58
Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology (2011) 1.58
The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology (2009) 1.58
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet (2010) 1.55
Development of the bile ducts: essentials for the clinical hepatologist. J Hepatol (2012) 1.55
Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol (1997) 1.52
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology (1997) 1.45
Medical and surgical treatment options for polycystic liver disease. Hepatology (2010) 1.39
Clinical profile of autosomal dominant polycystic liver disease. Hepatology (2003) 1.37
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol (2009) 1.36
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol (2010) 1.36
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab (2008) 1.31
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30
Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med (2005) 1.28
Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology (2011) 1.26
Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int (2001) 1.25
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant (2012) 1.20
Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology (2010) 1.20
Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther (2011) 1.19
The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther (2011) 1.17
Tailoring the management of nonparasitic liver cysts. Ann Surg (1998) 1.17
Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2008) 1.12
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol (2008) 1.12
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11
Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat (2006) 1.10
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol (2007) 1.10
Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke (2010) 1.10
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (2012) 1.09
Isolated polycystic liver disease. Adv Chronic Kidney Dis (2010) 1.08
Liver transplantation: the current situation. Semin Liver Dis (2009) 1.07
Liver transplantation for polycystic liver disease. Liver Transpl (2001) 1.06
Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. J Hepatol (2009) 1.06
Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg (1997) 1.06
Surgical management of polycystic liver disease. World J Gastroenterol (2007) 1.06
Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int (2009) 1.05
Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results. Eur Radiol (2003) 1.04
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02
Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl (2006) 1.01
Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol (2011) 1.01
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
Polycystins, focal adhesions and extracellular matrix interactions. Biochim Biophys Acta (2011) 0.98
Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg (2007) 0.98
Intravascular embolization therapy in a patient with an enlarged polycystic liver. Am J Kidney Dis (2004) 0.94
Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther (2003) 0.93
Natural history of autosomal dominant polycystic kidney disease. Annu Rev Med (1994) 0.91
SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology (2002) 0.90
Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging (2008) 0.89
Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig Dis Sci (2008) 0.89
Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2010) 0.83
Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 0.82
Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials (2011) 0.82
Somatic second-hit mutations leads to polycystic liver diseases. World J Gastroenterol (2013) 0.81
Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic. BMC Nephrol (2012) 0.81
Congenital fibrocystic liver diseases. Best Pract Res Clin Gastroenterol (2010) 0.81
Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum. Neth J Med (2011) 0.81
It's not all in the cilium, but on the road to it: genetic interaction network in polycystic kidney and liver diseases and how trafficking and quality control matter. J Hepatol (2011) 0.80
Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series. BMC Nephrol (2011) 0.80
ERCP for the treatment of bile leak after partial hepatectomy and fenestration for symptomatic polycystic liver disease. World J Gastroenterol (2012) 0.80
Treatment of polycystic liver disease. Br J Surg (2009) 0.78
Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease. Liver Int (2011) 0.78
Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil. Abdom Imaging (2013) 0.78
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol (2011) 3.53
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol (2004) 1.90
Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A (2010) 1.79
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol (2013) 1.79
Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med (2003) 1.76
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
Short mucin 6 alleles are associated with H pylori infection. World J Gastroenterol (2006) 1.67
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology (2011) 1.58
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci (2009) 1.34
Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain (2011) 1.32
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30
Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med (2004) 1.29
2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol (2005) 1.26
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25
Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.24
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther (2004) 1.23
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology (2007) 1.12
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11
Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat (2006) 1.10
Proliferation of authors on research reports in medicine. Sci Eng Ethics (1996) 1.09
Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain (2011) 1.09
Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. J Hepatol (2009) 1.06
Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int (2009) 1.05
Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol (2005) 1.04
Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. Brain (2010) 1.04
HCV treatment--no more room for interferonologists? N Engl J Med (2013) 1.03
Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood (2006) 1.02
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02
Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol (2011) 1.01
Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci U S A (2014) 1.00
Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg (2007) 0.98
High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk. Int J Oncol (2012) 0.95
GWAS-uncovered SNPs in PLCE1 and RFT2 genes are not implicated in Dutch esophageal adenocarcinoma and squamous cell carcinoma etiology. Eur J Cancer Prev (2013) 0.95
FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging (2004) 0.93
Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons. Nat Rev Neurol (2010) 0.93
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol (2010) 0.92
Familial Mediterranean fever--a not so unusual cause of abdominal pain. Best Pract Res Clin Gastroenterol (2005) 0.92
Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer (2013) 0.91
Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med (Berl) (2006) 0.91
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int (2007) 0.91
Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction? J Hepatol (2008) 0.90
A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med (2003) 0.90
Effect of octreotide on polycystic liver volume. Liver Int (2009) 0.90
Genetic factors in chronic pancreatitis; implications for diagnosis, management and prognosis. Best Pract Res Clin Gastroenterol (2010) 0.90
Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig Dis Sci (2008) 0.89
A loss of function polymorphism (G191R) of anionic trypsinogen (PRSS2) confers protection against chronic pancreatitis. Pancreas (2008) 0.88
Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol (2014) 0.88
Dysregulation of innate immunity: hereditary periodic fever syndromes. Br J Haematol (2008) 0.88
Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochem Cell Biol (2008) 0.88
Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther (2012) 0.88
[18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res (2004) 0.88
Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. Liver Int (2011) 0.88
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit (2011) 0.87
Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol (2008) 0.87
Upper gastrointestinal endoscopy in patients aged 85 years or more. Results of a feasibility study in a district general hospital. Arch Gerontol Geriatr (2003) 0.87
Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int (2014) 0.87
A new Nav1.7 sodium channel mutation I234T in a child with severe pain. Eur J Pain (2010) 0.86
Tropical calcific pancreatitis and its association with CTRC and SPINK1 (p.N34S) variants. Eur J Gastroenterol Hepatol (2009) 0.86
Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig Dis Sci (2006) 0.86
Patient-reported outcomes of symptomatic cholelithiasis patients following cholecystectomy after at least 5 years of follow-up: a long-term prospective cohort study. Surg Endosc (2014) 0.86
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet (2014) 0.85
Genetic polymorphisms in alcohol-metabolizing enzymes and chronic pancreatitis. Alcohol Alcohol (2003) 0.85
Assessment of oxidative stress in chronic pancreatitis patients. World J Gastroenterol (2006) 0.85
Pulmonary sclerosing hemangioma detected by fluorodeoxyglucose positron emission tomography in familial adenomatous polyposis: report of a case. Dis Colon Rectum (2007) 0.85
Ability of FDG-PET to detect all cancers in patients with familial adenomatous polyposis, and impact on clinical management. Eur J Nucl Med Mol Imaging (2005) 0.84
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther (2009) 0.84
EPHX1 polymorphisms do not modify esophageal carcinoma susceptibility in Dutch Caucasians. Oncol Rep (2012) 0.83
Persistent and de novo symptoms after cholecystectomy: a systematic review of cholecystectomy effectiveness. Surg Endosc (2012) 0.83
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. Br J Clin Pharmacol (2005) 0.83
Rising incidence of celiac disease in the Netherlands; an analysis of temporal trends from 1995 to 2010. Scand J Gastroenterol (2014) 0.83
Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia. Mol Pain (2008) 0.82
Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int (2014) 0.82
Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials (2011) 0.82
Divergent roles of SPINK1 and PRSS2 variants in tropical calcific pancreatitis. Pancreatology (2008) 0.82
Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS One (2012) 0.82
High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis (2012) 0.81
Functional polymorphisms of UDP-glucuronosyltransferases 1A1, 1A6 and 1A8 are not involved in chronic pancreatitis. Pharmacogenetics (2004) 0.81
Glutathione S-transferase Mu null genotype affords protection against alcohol induced chronic pancreatitis. Am J Med Genet A (2003) 0.81
Polymorphisms in gene encoding TRPV1-receptor involved in pain perception are unrelated to chronic pancreatitis. BMC Gastroenterol (2009) 0.80
A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's disease. J Crohns Colitis (2007) 0.80
Gastroparesis in patients with inactive Crohn's disease: a case series. BMC Gastroenterol (2007) 0.80
The role of epoxide hydrolase Y113H gene variant in pancreatic diseases. Pancreas (2009) 0.80
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. BMC Gastroenterol (2010) 0.80
Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. Liver Int (2013) 0.79
18F-FDG PET/CT during diagnosis and follow-up of recurrent hepatic cyst infection in autosomal dominant polycystic kidney disease. Clin Nephrol (2015) 0.79
Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J Antimicrob Chemother (2013) 0.79
FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol (2005) 0.79
A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS One (2012) 0.79